/

HEPA

Hepion Pharmaceuticals, Inc.Closed

0.0610−0.06 −50.81%USD

OTC Markets OTCQB · as of Oct 13, 16:00 ET · 15m delay

Open

0.0900

Prev close

0.1240

Day range

0.06100.1250

52-week range

0.03400.1320

Volume

36.19K0.89×

Mkt cap

7.52M

P/E ttm

—

Fwd P/E

-0.01

EPS ttm

-0.1900

Div yield

0.00%

Earnings

—

From 52w high

−53.79%

Price Chart

Yahoo Finance · delayed

HEPAOct 13, 2026O 0.1200H 0.1340L 0.0610C 0.0610−0.0630 (−50.81%)Vol 72.10K

SMA 500.0791
SMA 2000.0622

1Y change −23.75% since Oct 13, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

HEPA Hepion Pharmaceuticals, Inc. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −49.17%
1 month: −14.08%
3 months: +1.67%
6 months: +27.08%
Year to date: +1.67%
1 year: −23.75%

Valuation & ownership

Market cap: 7.52M
Enterprise value: 5.57M
P/E (ttm): —
Forward P/E: -0.01
PEG ratio: —
Price / book: —
Price / sales (ttm): —
EV / EBITDA: —
EPS (ttm): -0.1900
EPS (forward): -11.43
Beta (5y monthly): 1.75
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 123.22M
Float: 43.19M
Short % of float: 4.10%
Short ratio (days): 0.05
Held by insiders: 52.95%
Held by institutions: 0.00%
Avg volume (3m): 40.80K
50-day average: 0.0793
200-day average: 0.0622
52-week change: −23.75%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 41.3
vs 50-day SMA: −22.86%
vs 200-day SMA: −1.90%
50 / 200-day trend: ▲ 50 above 200
MACD vs signal: ▼ below
ATR (14) % of price: 36.26%
Realised vol (20d, ann.): 342.5%
From 52-week high: −54.48%
From 52-week low: +79.41%

ANR

Analyst Consensus

No analyst coverage for this instrument.

Financial Snapshot

Full statements →trailing twelve months

Revenue (ttm): —
Revenue growth (yoy): —
Earnings growth (yoy): —
Gross margin: 0.00%
Operating margin: 0.00%
Profit margin: 0.00%

DES

About Hepion Pharmaceuticals, Inc.

Yahoo Finance profile

Hepion Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of treatment for hepatocellular carcinoma (HCC), metabolic liver diseases, and chronic liver diseases in the United States. It developed Rencofilstat, a therapeutic drug candidate that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulates protein folding, as well as preclinical experiments of Rencofilstat reflects decreased liver fibrosis; liver inflammation; liver tumor burden; and titers of HBV, HCV, and HDV. The company was formerly known as ContraVir Pharmaceuticals, Inc. and changed its name to Hepion Pharmaceuticals, Inc. in July 2019. Hepion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Morristown, New Jersey.

Sector: Healthcare
Industry: Biotechnology
Employees: 2
Headquarters: Morristown, NJ, United States
Website: hepionpharma.com
Officers: Mr. Vincent LoPriore Executive Chairman
Mr. Gary S. Stetz CPA Interim CEO & Director
Sharen Pyatetskaya Director of Investor Relations

SEAS

Seasonality · HEPA

2014–2026 · monthly returns

Strongest month Oct +9.80%Weakest month Apr −19.91%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-41.7	14.3	42.5	10.5	4.8	3.0	-32.4	73.9	42.5	-46.5			+1.7%
2025	-61.7	-30.0	-93.2	-32.8	-81.0	45.5	-47.5	59.5	-25.4	34.0	-3.0	-7.7	−99.7%
2024	-41.4	56.3	-16.2	-45.2	-7.7	-19.0	-23.2	7.0	-20.0	-1.6	1.4	-29.6	−85.5%
2023	143.3	19.7	-11.1	-10.4	-31.0	9.4	-24.3	-6.3	-33.0	-6.4	-31.0	0.6	−46.0%
2022	-14.0	12.2	17.3	-28.1	-15.9	-26.5	-5.8	26.5	-26.1	5.5	-31.5	-17.8	−73.7%
2021	-5.9	-8.7	-2.1	-6.0	-1.7	16.5	-22.2	4.5	-5.0	-6.5	-13.3	-8.1	−47.9%
2020	-3.4	-30.9	-50.6	5.6	-1.1	54.6	41.3	-18.1	-6.0	-13.5	-37.9	31.1	−59.1%
2019	9.9	-22.9	-5.9	-43.6	-15.7	-44.3	-29.0	-17.2	-1.2	29.8	122.6	-23.3	−72.8%
2018	-16.9	-16.4	-6.0	6.4	-11.0	-27.0	-45.3	4.1	-24.2	-10.9	3.6	-45.6	−90.2%
2017	18.3	-0.7	25.5	-52.5	-26.8	-5.7	3.4	-20.8	9.5	-4.0	-1.2	-27.0	−70.0%
2016	-38.3	-7.4	37.5	-17.4	-13.0	19.5	-2.9	13.9	-7.0	88.8	-2.0	-39.4	−22.1%
2015	18.0	63.7	-28.2	1.9	24.0	30.6	-5.5	-21.9	-44.3	-23.0	40.4	-31.9	−30.6%
2014			44.2	-16.9	-17.6	-27.9	13.5	2.4	-20.3	25.5	4.7	64.4	+42.3%

INSD

Insider Activity · HEPA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Aug 2, 2026	Stetz Gary SChief Executive Officer	Purchase at price 0.07 per share.	2.00M	$143.20K
Aug 2, 2026	Purcell Michael J.Director	Purchase at price 0.07 per share.	2.00M	$143.20K
Aug 2, 2026	Appajosyula SireeshChief Operating Officer	Purchase at price 0.07 per share.	2.00M	$143.20K
Aug 2, 2026	Lopriore Vincent SOfficer and Director	Purchase at price 0.07 per share.	10.00M	$716.00K
Apr 20, 2026	Stetz Gary SChief Executive Officer	Purchase at price 0.04 per share.	1.25M	$50.00K
Apr 20, 2026	Purcell Michael J.Director	Purchase at price 0.04 per share.	1.25M	$50.00K
Apr 20, 2026	Appajosyula SireeshDirector	Purchase at price 0.04 per share.	1.25M	$50.00K
Apr 20, 2026	Lopriore Vincent SOfficer, Director and Beneficial Owner	Purchase at price 0.04 per share.	6.25M	$250.00K

HEPA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

HEPA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Hepion Pharmaceuticals, Inc.

Seasonality · HEPA

Insider Activity · HEPA

Congress Trades · HEPA

Investors Holding HEPA

Investors Holding HEPA

Congress Trades · HEPA

Insider Activity · HEPA

Seasonality · HEPA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

Financial Snapshot

About Hepion Pharmaceuticals, Inc.

Earnings & Dividends

News